Gold nanorods conjugated with doxorubicin and cRGD for combined anti-cancer drug delivery and PET imaging

Theranostics

Volumn 2, Issue 8, 2012, Pages 757-768

  Xiao, Yuling ^a   Hong, Hao ^b,c   Matson, Vyara Z ^d   Javadi, Alireza ^a   Xu, Wenjin ^a   Yang, Yunan ^b   Zhang, Yin ^c   Engle, Jona than W ^c   Nickles, Robert J ^b,c   Cai, Weibo ^b,c   Steeber, Douglas A ^d   Gong, Shaoqin ^a  

^a University of Wisconsin Madison   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Cancer; cRGD peptide; Drug delivery; Gold nanorod (GNR); Nanoparticles; Positron emission tomography (PET); Tumor targeting

Indexed keywords

AMINO ACID; CYCLO (ARGINYL GLYCYL ASPARGINYL DEXTRO PHENILALANYL CYSTEINE) PEPTIDE DERIVATIVE; DOXORUBICIN; GOLD NANOPARTICLE; MACROGOL; NANOCARRIER; NANOROD; NITRILOTRIACETATE COPPER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MOUSE; NONHUMAN; PH; POSITRON EMISSION TOMOGRAPHY;

EID: 84866019890     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4756     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano. 2007; 2: 751-60.
4. Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005; 5: 65-72.
5. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153: 198-205.
6. Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011; 44: 999-1008.
7. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-71.
8. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012; 2: 3-44.
9. Huang P, Xu C, Lin J, Wang C, Wang X, Zhang C, et al. Folic acid-conjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy. Theranostics. 2011; 1: 240-50.
10. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst. 2005; 1: 242-50.
11. Bae Y, Kataoka K. Significant enhancement of antitumor activity and bioavailability of intracellular pH-sensitive polymeric micelles by folate conjugation. J Control Release. 2006; 116: e49-50.
12. Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the national cancer institute alliance for nanotechnology in cancer. ACS Nano. 2010; 4: 589-94.
13. Gunasekera UA, Pankhurst QA, Douek M. Imaging applications of nanotechnology in cancer. Target Oncol. 2009; 4: 169-81.
14. Guo S, Qiao Y, Wang W, He H, Deng L, Xing J, et al. Poly([varepsilon]-caprolactone)-graft-poly(2-(N, N-dimethylamino) ethyl methacrylate) nanoparticles: pH dependent thermo-sensitive multifunctional carriers for gene and drug delivery. J Mater Chem. 2010; 20: 6935-41.
15. Yong KT, Roy I, Swihart MT, Prasad PN. Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. J Mater Chem. 2009; 19: 4655-72.
16. Patra CR, Bhattacharya R, Mukherjee P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010; 20: 547-54.
17. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9: 615-27.
18. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010; 146: 219-27.
19. Rosi NL, Mirkin CA. Nanostructures in biodiagnostics. Chem Rev. 2005; 105: 1547-62.
20. Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD, et al. Combining portable raman probes with nanotubes for theranostic applications. Theranostics. 2011; 1: 310-21.
21. Choi J, Yang J, Park J, Kim E, Suh J-S, Huh Y-M, et al. Specific near-IR absorption imaging of glioblastomas using integrin-targeting gold nanorods. Adv Funct Mater. 2011; 21: 1082-8.
22. Zhang F, Zhu L, Liu G, Hida N, Lu G, Eden HS, et al. Multimodality imaging of tumor response to doxil. Theranostics. 2011; 1: 302-9.
23. Kessinger CW, Togao O, Khemtong C., Huang G, Takahashi M, Gao JM. Investigation of in vivo targeting kinetics of αvβ3-specific superparamagnetic nanoprobes by time-resolved MRI. Theranostics. 2011; 1: 263-73.
24. Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today. 2009; 4: 399-413.
25. Townsend DW. Dual-Modality Imaging: Combining Anatomy and Function. J Nucl Med. 2008; 49: 938-55.
26. Jennings LE, Long NJ. 'Two is better than one'-probes for dual-modality molecular imaging. Chem Commun. 2009; 28: 3511-24.
27. Zhang Y, Yang Y, Cai W. Multimodality imaging of integrin αvβ3 expression. Theranostics. 2011; 1: 135-48.
28. Joshi BP, Wang TD. Exogenous molecular probes for targeted imaging in cancer: focus on multi-modal imaging. Cancers (Basel). 2010; 2: 1251-87.
29. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001; 19: 316-7.
30. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006; 128: 2115-20.
31. Kuo W-S, Chang C-N, Chang Y-T, Yang M-H, Chien Y-H, Chen S-J, et al. Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew Chem Int Ed. 2010; 49: 2711-5.
32. Murphy CJ, Gole AM, Hunyadi SE, Stone JW, Sisco PN, Alkilany A, et al. Chemical sensing and imaging with metallic nanorods. Chem Commun (Camb). 2008;: 544-57.
33. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208.
34. Chakravarthy KV, Bonoiu AC, Davis WG, Ranjan P, Ding H, Hu R, et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc Natl Acad Sci U S A. 2010; 107: 10172-7.
35. Huang H-C, Rege K, Heys JJ. Spatiotemporal Temperature Distribution and cancer cell death in response to extracellular hyperthermia induced by gold nanorods. ACS Nano. 2010; 4: 2892-900.
36. von Maltzahn G, Centrone A, Park J-H, Ramanathan R, Sailor MJ, Hatton TA, et al. SERS-coded gold nanorods as a multifunctional platform for densely multiplexed near-infrared imaging and photothermal heating. Adv Mater. 2009; 21: 3175-80.
37. Nasongkla N, Shuai X, Ai H, Weinberg BD, Pink J, Boothman DA, et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl. 2004; 43: 6323-7.
38. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987; 238: 491-7.
39. Chen X. Integrin targeted imaging and therapy. Theranostics. 2011; 2011: 28-9.
40. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006; 6: 669-76.
41. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011; 38: 1335-43.
42. Nikoobakht B, El-Sayed MA. Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated growth method. Chem Mater. 2003; 15: 1957-62.
43. Sau TK, Murphy CJ. Seeded high yield synthesis of short Au nanorods in aqueous solution. Langmuir. 2004; 20: 6414-20.
44. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a humanized monoclonal antibody against integrin αvβ3. Cancer Res. 2006; 66: 9673-81.
45. Xiao Y, Hong H, Javadi A, Engle JW, Xu W, Yang Y, et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials. 2012; 33: 3071-82.
46. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, et al. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011; 32: 4151-60.
47. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79: 1157-64.
48. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47.
49. Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011; 1: 189-200.
50. Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007; 48: 1862-70.
51. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007; 2: 47-52.
52. Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small. 2007; 3: 1840-54.
53. Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA, et al. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010; 4: 5887-96.